☰
✕

Circulating cell free tumor dna market

Circulating Cell-Free Tumor DNA Market, by Tumor Type (Malignant Tumors, Precancerous Tumors), by Cancer Type (Lung Cancer, Colorectal Cancer, Breast Cancer, Others) by Technology (PCR, Massively Parallel Sequencing, Single Nucleotide Polymorphism), by Application (Cancer Diagnosis, Targeting Therapeutics, Prognosis Indication), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Request Free Sample
  • Jun 2023
  • CMI5819
  • 190 Pages
  • Excel & Pdf
  • Biotechnology

The global Circulating Cell-free Tumor DNA Market is estimated to be valued at US$ 6.1 billion in 2023 and is expected to exhibit a CAGR of 22.9% during the forecast period (2023-2030).

Analysts’ Views on Global Circulating Cell-free Tumor DNA Market:

The global Circulating Cell-free Tumor DNA Market's growth can be hindered by disadvantages associated with circulating cell-free tumor DNA analysis like some tests require prior knowledge of tumor mutations, results can be semiquantitative,etc. The use of circulating cell-free tumor DNA tests for the diagnosis of cancer is expected to drive the global Circulating Cell-free Tumor DNA Market over the forecast period. For instance, in January 2022, a report published by Springer Nature Limited, a scientific journal, stated that cell-free tumor DNA analysis represents a promising method for the diagnosis, treatment selection, and clinical follow-up of cancer patients.

Figure 1. Global Circulating Cell-free Tumor DNA Market Share (%), by Application, 2023

Global Circulating Cell-free Tumor DNA Market – Driver

Increasing product launches by key players in the market 

Increasing product launches by key players in the market to expand their product portfolio is expected to drive market growth over the forecast period. For instance, Foundation Medicine, a manufacturer of genomic profiling assays based on next-generation sequencing technology, and Natera, a global leader in cell-free DNA (cfDNA) testing announced the launch of an early access program for the investigational and clinical use of FoundationOne Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.

Figure 2. Global Circulating Cell-free Tumor DNA Market Value (US$ billion), by Region, 2023

Global Circulating Cell-free Tumor DNA Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global Circulating Cell-free Tumor DNA Market over the forecast period. North America holds 45.1% of the market share due to the increasing prevalence of cancer in the region. For instance, according to the American Cancer Society, a scientific cancer journal, in the year 2021, an estimated 1.9 million new cancer cases were diagnosed and 608,570 cancer deaths occurred in the U.S. due to cancer.

Global Circulating Cell-free Tumor DNA Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

The COVID-19 pandemic had a negative impact on the global Circulating Cell-free Tumor DNA Market. For instance, in September 2020, according to an article published by the American Society of Clinical Oncology, a professional organization committed to conquering cancer through research, education, prevention, and delivery of high-quality patient care, stated that a detrimental impact of the COVID-19 pandemic on cancer care was observed during the COVID-19 pandemic.

Circulating Cell-free Tumor DNA Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 6.1 Bn
Historical Data for: 2017 to 2021 Forecast Period: 2023 to 2030
Forecast Period 2023 to 2030 CAGR: 22.9% 2030 Value Projection: US$ 25.88 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Tumor Type: Malignant Tumors, Precancerous Tumors
  • By Cancer Type: Lung Cancer, Blood Stream Infections, Breast Cancer, Others
  • By Technology: PCR, Massively Parallel Sequencing, Single Nucleotide Polymorphism 
  • By Application: Cancer Diagnosis, Targeting Therapeutics, Prognosis Indication
Companies covered:

Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
Growth Drivers:
  • Increasing product launches by key players
Restraints & Challenges:
  • Disadvantages associated with circulating cell-free tumor DNA

Global Circulating Cell-free Tumor DNA Market Segmentation:

The global Circulating Cell-free Tumor DNA Market report is segmented into Tumor Type, Cancer Type, Technology, Application, and Region

Based on Tumor Type, the market is segmented into malignant tumors and precancerous tumors. Out of which, the precancerous tumors segment is expected to hold a dominant position in the Circulating Cell-free Tumor DNA Market during the forecast period and this is attributed to the increasing usage of circulating cell-free tumor DNA analysis for early detection of cancer.

Based on Cancer Type, the market is segmented into lung cancer, colorectal cancer, breast cancer, and others. Out of which, the lung cancer segment is expected to hold a dominant position in the Circulating Cell-free Tumor DNA Market during the forecast period and this is attributed to the increasing prevalence of lung cancer.

Based on Technology, the Circulating Cell-free Tumor DNA Market is segmented into PCR, massively parallel sequencing, and single nucleotide polymorphism. The massively parallel sequencing segment is expected to dominate the market over the forecast period and this is to the increasing usage of massively parallel sequencing for the detection of cancer DNA.

Based on Application, the Circulating Cell-free Tumor DNA Market is segmented into cancer diagnosis, targeting therapeutics, and prognosis indication. The cancer diagnosis segment is expected to dominate the market over the forecast period and this is to the increasing usage of cancer diagnosis methods.

Among all segmentation, the application segment has the highest potential due to the increasing prevalence of cancer over the forecast period. For instance, in April 2021, according to a report published by American Medical Association, a scientific community, stated that Lung cancer is estimated to continue as the leading cause of cancer-related death in 2040 with an estimated 63,000 deaths.

Global Circulating Cell-free Tumor DNA Market Cross Sectional Analysis:

In cancer type segment, lung cancer holds a dominant segment in North America region due to the increasing prevalence of lung cancer. For instance, in November 2022, an article published by Jobson Medical Information LLC, a premier healthcare information and marketing services company, stated that approximately 236,740 new cases of lung cancer were projected in the year 2022.

Global Circulating Cell-free Tumor DNA Market: Key Developments

  • Increasing research and development activities and product launch by key players in the market is expected to generate new opportunities in the global Circulating Cell-free Tumor DNA Market.
  • On 10 January 2023, Grail, a biotechnology company, announced the launch of a targeted methylation platform to analyze cell-free DNA (cfDNA) isolated from peripheral blood for cancer signal interrogation.
  • In August 2020, CLOVIS ONCOLOGY, a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test for all solid tumors with multiple companion diagnostic indications, including for Rubraca (rucaparib) tablets, recently approved for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer.
  • In October 2021, Natera, Inc., a global leader in cell-free DNA (cfDNA) testing announced the publication of a new study in Clinical Cancer Research demonstrating the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to assess tumor growth rates and predict patient survival in early-stage colorectal cancer (CRC).
  • In August 2021, Illumina, Inc. a biotechnology company, announced that it has acquired GRAIL, a healthcare company focused on the life-saving early detection of multiple cancers. GRAIL's Galleri blood test detects 50 different cancers before they are symptomatic. Illumina's acquisition of GRAIL will accelerate access and adoption of this life-saving test worldwide.

Global Circulating Cell-free Tumor DNA Market: Key Trends

Increasing prevalence and factors associated with cancer

Increasing prevalence of cancer needs effective factors for the management of cancer which is expected to drive the monoclonal antibody therapeutics market growth over the forecast period. For instance, in February 2021, an article published by the American Cancer Society, a scientific journal, stated that almost 10.0 million cancer deaths occurred in the year 2020.

Global Circulating Cell-free Tumor DNA Market: Restraint

Disadvantages of circulating cell-free tumor DNA analysis

The global Circulating Cell-free Tumor DNA Market can be hindered by disadvantages associated with circulating cell-free tumor DNA. For instance, in January 2022, a report published on MDPI, a publisher of open-access scientific journals, stated the disadvantages of cell-free tumor DNA detection are that some tests require prior knowledge of tumor mutations, results can be semi-quantitative, the source of cfDNA can be from multiple sources (apoptosis, graft rejection, immune cells vs. tumor cells, etc.). ) and analytical methods may involve technical difficulties.

Global Circulating Cell-free Tumor DNA Market - Key Players

Major players operating in the global Circulating Cell-free Tumor DNA Market include Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.

Global Circulating Cell-free Tumor DNA Market– Insights

The term "circulating tumor DNA" (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Tumor Type
      • Market Snapshot, By Cancer Type
      • Market Snapshot, By Technology
      • Market Snapshot, By Application
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product Launch
    • Technological Advancements
    • PEST Analysis
    • Regulatory Scenario
    • Mergers and Acquisitions
  4. Global Circulating Cell-free Tumor DNA Market– COVID-19 Impact Analysis
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand
  5. Global Circulating Cell-free Tumor DNA Market, By Tumor Type, 2018 – 2030, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Malignant Tumors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
    • Precancerous Tumors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
  6. Global Circulating Cell-free Tumor DNA Market, By Cancer Type, 2018 – 2030, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segments Trends
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
    • Colorectal Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
  7. Global Circulating Cell-free Tumor DNA Market, By Technology, 2018 – 2030, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segments Trends
    • PCR
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
    • Massively Parallel Sequencing
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
    • Single Nucleotide Polymorphism
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
  8. Global Circulating Cell-free Tumor DNA Market, By Application, 2018 – 2030, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, 2018 – 2030
      • Segment Trends
    • Cancer Diagnosis    
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
    • Targeting Therapeutics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
    • Prognosis Indication
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018–2030, (US$ Billion)
  9. Global Circulating Cell-free Tumor DNA Market, By Region, 2018 – 2030, (US$ Billion)
    • Introduction
      • Market Share Analysis, By Region, 2023 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Billion)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Billion)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Billion)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Billion)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Billion)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
      • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 – 2030, (US$ Billion)
        • North Africa
        • Central Africa
        • South Africa
  10. Competitive Landscape
    • Biocept, Inc.*
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Illumina, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Quest Diagnostics Incorporated
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • KURABO INDUSTRIES LTD
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • PerkinElmer chemagen Technologie GmbH
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Biodesix
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Guardant Health
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • QIAGEN
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sequenom, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Agilent Technologies, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Fluxion Biosciences Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Natera, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Agena Bioscience, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Paragon Genomics, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Lucence Health Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Eurofins Genomics
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Thermo Fisher Scientific
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  11. Section
    • Research Methodology
    • About Us

*Browse 35 market data tables and 34 figures on “Global Circulating Cell-free Tumor DNA Market” - Global forecast to 2030

Detailed Segmentation:

  • Global Circulating Cell-free Tumor DNA Market, By Tumor Type:
    • Malignant Tumors
    • Precancerous Tumors
  • Global Circulating Cell-free Tumor DNA Market, By Cancer Type:
    • Lung Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • Global Circulating Cell-free Tumor DNA Market, By Technology:
    • PCR
    • Massively Parallel Sequencing
    • Single Nucleotide Polymorphism
  • Global Circulating Cell-free Tumor DNA Market, By Application:
    • Cancer Diagnosis
    • Targeting Therapeutics
    • Prognosis Indication
  • Global Circulating Cell-free Tumor DNA Market, By Region:
    • North America
      • By Tumor Type:
        • Malignant Tumors
        • Precancerous Tumors
      • By Cancer Type:
        • Lung Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Technology:
        • PCR
        • Massively Parallel Sequencing
        • Single Nucleotide Polymorphism
      • By Application:
        • Cancer Diagnosis
        • Targeting Therapeutics
        • Prognosis Indication
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Tumor Type:
        • Malignant Tumors
        • Precancerous Tumors
      • By Cancer Type:
        • Lung Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Technology:
        • PCR
        • Massively Parallel Sequencing
        • Single Nucleotide Polymorphism
      • By Application:
        • Cancer Diagnosis
        • Targeting Therapeutics
        • Prognosis Indication
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Tumor Type:
        • Malignant Tumors
        • Precancerous Tumors
      • By Cancer Type:
        • Lung Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Technology:
        • PCR
        • Massively Parallel Sequencing
        • Single Nucleotide Polymorphism
      • By Application:
        • Cancer Diagnosis
        • Targeting Therapeutics
        • Prognosis Indication
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Tumor Type:
        • Malignant Tumors
        • Precancerous Tumors
      • By Cancer Type:
        • Lung Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Technology:
        • PCR
        • Massively Parallel Sequencing
        • Single Nucleotide Polymorphism
      • By Application:
        • Cancer Diagnosis
        • Targeting Therapeutics
        • Prognosis Indication
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Tumor Type:
        • Malignant Tumors
        • Precancerous Tumors
      • By Cancer Type:
        • Lung Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Technology:
        • PCR
        • Massively Parallel Sequencing
        • Single Nucleotide Polymorphism
      • By Application:
        • Cancer Diagnosis
        • Targeting Therapeutics
        • Prognosis Indication
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Tumor Type:
        • Malignant Tumors
        • Precancerous Tumors
      • By Cancer Type:
        • Lung Cancer
        • Colorectal Cancer
        • Breast Cancer
        • Others
      • By Technology:
        • PCR
        • Massively Parallel Sequencing
        • Single Nucleotide Polymorphism
      • By Application:
        • Cancer Diagnosis
        • Targeting Therapeutics
        • Prognosis Indication
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global circulating cell-free tumor DNA market during the forecast period (2023-2030)?

The global circulating cell-free tumor DNA market is estimated to be valued at US$ 6.1 billion in 2023 and is expected to exhibit a CAGR of 22.9% between 2023 and 2030.

What are the major factors driving the market growth?

Increasing product launches by key players in the market is expected to drive the market growth.

Which is the leading tumor type segment in the market?

Precancerous Tumors is the leading tumor type segment in the market.

What are the key factors hampering the growth of the market?

Disadvantages associated with circulating cell-free tumor DNA is expected to hinder the market over the forecast period.

Which are the major players operating in the market?

Major players operating in the market include Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Buy Now with Special Discount
Customize Now